TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03345914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Topical Corticosteroids
Description: All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Topical Corticosteroids
Description: All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Moisturizers
Description: All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Moisturizers
Description: All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Moisturizers
Description: All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
Study: NCT03473171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal non-invasive ventilation with RAM cannula
Description: Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
Study: NCT02153333

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
Study: NCT04459728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1: Exercise
Description: Daily wellness element focusing on Exercise; adherence documented online daily
Study: NCT01235949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study: NCT02457611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01235949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study: NCT03885596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-008
Description: Drug: CA-008 4.2 mg reconstituted in saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-008
Description: Drug: CA-008 4.2 mg reconstituted in saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-008
Description: Drug: CA-008 4.2 mg reconstituted in saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery
Study: NCT04956822

Intervention type: OTHER
Intervention: Functional scores
Description: depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores

Intervention type: OTHER
Intervention: Functional scores
Description: depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores

Intervention type: DEVICE
Intervention: MINUX
Description: MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.

Intervention type: DEVICE
Intervention: MINUX
Description: MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.

Intervention type: DEVICE
Intervention: MINUX
Description: MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.

Intervention type: DEVICE
Intervention: MINUX
Description: MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
Study: NCT03007745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoadjusting continuous positive airway pressure
Description: Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoadjusting continuous positive airway pressure
Description: Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo
Study: NCT00921284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9/00
Description: Same volume as in the dexmedetomidine group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
Study: NCT00760526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitor
Description: Daily use of a continuous glucose monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home blood glucose monitor
Description: Home monitoring 3 or more times a day
Study: NCT03309202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 25 mg dose
Study: NCT03885596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: 1.5% 12 mL at the end of surgery
Study: NCT03699202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
Study: NCT02385071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.
Study: NCT03885596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg PO bid each day postoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg PO bid each day postoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Oral
Description: 1 g postoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Oral
Description: 1 g postoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 2% 15 mL at the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 2% 15 mL at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 2% 15 mL at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Bupivacaine liposome injection suspension
Study: NCT02716324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Manager CM)
Description: The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
Study: NCT02385071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.
Study: NCT02716324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Portal
Description: The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Portal
Description: The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
Study: NCT01465243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
Study: NCT01006551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
Study: NCT02983370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minicraniotomy
Description: The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
Study: NCT02385071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
Study: NCT04302519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dental pulp mesenchymal stem cells
Description: On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
Study: NCT05171218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music & Auditory Beat Stimulation
Description: Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Alone
Description: Listening to calm music Participants listened to calm music for 24 minutes
Study: NCT05171218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Beat Stimulation
Description: Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pink Noise
Description: Listening to pink noise Participants listened to pink noise for 24 minutes
Study: NCT02526641

Intervention type: PROCEDURE
Intervention: Functional Hepatic Nitrogen Clearance (FHNC)

Intervention type: PROCEDURE
Intervention: Galactose Elimination Capacity (GEC)

Intervention type: PROCEDURE
Intervention: Liver vein catheterization
Study: NCT03168646

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wafer procedure
Description: wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy and ulnar shortening osteotomy
Description: wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate